BridgeBio Pharma, Inc. Repayments of Long-Term Debt
BridgeBio Pharma, Inc. (BBIO) reported Repayments of Long-Term Debt of $459.00 million for the 6-month period ending 2025-06-30, per its 10-Q filed 2025-08-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:RepaymentsOfLongTermDebt · last filed 2025-08-05
- BridgeBio Pharma, Inc. repayments of long-term debt for the quarter ending 2025-06-30 was $0.00.
- BridgeBio Pharma, Inc. repayments of long-term debt for the quarter ending 2025-03-31 was $459.00M, a 3.05% decline year-over-year.
- BridgeBio Pharma, Inc. repayments of long-term debt for the quarter ending 2024-12-31 was $0.00.
- BridgeBio Pharma, Inc. repayments of long-term debt for the quarter ending 2024-09-30 was $0.00.
- BridgeBio Pharma, Inc. repayments of long-term debt for fiscal 2024 was $473.42M.
- BridgeBio Pharma, Inc. repayments of long-term debt for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- BridgeBio Pharma, Inc. repayments of long-term debt for fiscal 2022 was $20.49M, a 83.49% decline from fiscal 2021.
- BridgeBio Pharma, Inc. repayments of long-term debt for fiscal 2021 was $124.12M.
| Period end | Repayments of Long-term Debt 3 month | Repayments of Long-term Debt 6 month | Repayments of Long-term Debt 9 month | Repayments of Long-term Debt 12 month |
|---|---|---|---|---|
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $459.00M 10-Q · filed 2025-08-05 | $459.00M derived: sum of 3 quarters · filed 2025-08-05 | $459.00M derived: sum of 4 quarters · filed 2025-08-05 |
| 2025-03-31 | $459.00M 10-Q · filed 2025-04-29 | $459.00M derived: sum of 2 quarters · filed 2025-04-29 | $459.00M derived: sum of 3 quarters · filed 2025-04-29 | $459.00M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $0.00 derived: sum of 2 quarters · filed 2025-02-20 | $0.00 derived: sum of 3 quarters · filed 2025-08-05 | $473.42M 10-K · filed 2025-02-20 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $0.00 derived: sum of 2 quarters · filed 2025-08-05 | $473.42M 10-Q · filed 2024-11-12 | $473.42M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $473.42M 10-Q · filed 2025-08-05 | $473.42M derived: sum of 3 quarters · filed 2025-08-05 | $473.42M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $473.42M 10-Q · filed 2025-04-29 | $473.42M derived: sum of 2 quarters · filed 2025-04-29 | $473.42M derived: sum of 3 quarters · filed 2025-04-29 | $473.42M derived: sum of 4 quarters · filed 2025-04-29 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $0.00 derived: sum of 2 quarters · filed 2025-02-20 | $0.00 derived: sum of 3 quarters · filed 2025-02-20 | $0.00 10-K · filed 2025-02-20 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $0.00 derived: sum of 2 quarters · filed 2024-11-12 | $0.00 10-Q · filed 2024-11-12 | $0.00 derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $0.00 10-Q · filed 2024-08-01 | $0.00 derived: sum of 3 quarters · filed 2025-02-20 | $0.00 derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-02 | $0.00 derived: sum of 2 quarters · filed 2025-02-20 | $0.00 derived: sum of 3 quarters · filed 2025-02-20 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $0.00 derived: sum of 2 quarters · filed 2025-02-20 | $20.49M 10-K · filed 2025-02-20 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $20.49M 10-Q · filed 2023-11-02 | ||
| 2022-06-30 | $20.49M 10-Q · filed 2023-08-03 | |||
| 2021-12-31 | $106.01M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $106.01M derived: sum of 2 quarters · filed 2024-02-22 | $124.12M 10-K · filed 2024-02-22 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $18.11M 10-Q · filed 2022-11-03 | ||
| 2021-06-30 | $18.11M 10-Q · filed 2022-08-04 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-02-23 | |||
| 2018-12-31 | $441.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $1.10M 10-K · filed 2021-02-25 | ||
| 2018-09-30 | $656.00K 10-Q · filed 2019-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |